A bispecific antibody to synergise checkpoint blockers in oncology

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000097

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer hides from the immune system in its earliest stages by evading immune surveillance and a cell type named myeloid derived suppressor cell (MDSC) has been identified as the main accomplice in this evasion. Currently, there is no drugs able to specifically target those cells. Here, we will develop a new drug that will prevent their recruitment to the tumors. We believe that when use in synergy with recent immunotherapies, it will dramatically improve survival in cancer patients.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Development Grants

Funding Amount: $636,492.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody engineering | chemokine receptor | immune evasion | tumour immunotherapy

Related Links